Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 478753, 12 pages
Research Article

TACI Expression and Signaling in Chronic Lymphocytic Leukemia

1Department of Immunology & Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis 3, 41500 Larissa, Greece
2Department of Hematology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis 3, 41500 Larissa, Greece
3Fourth Department of Internal Medicine, Ippokration Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece
4Department of Hematology, Papageorgiou General Hospital, Periferiaki Odos Thessalonikis, Nea Efkarpia, 56429 Thessaloniki, Greece

Received 20 November 2014; Accepted 15 March 2015

Academic Editor: Jacek Tabarkiewicz

Copyright © 2015 Antigoni Mamara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


TACI is a membrane receptor of BAFF and APRIL, contributing to the differentiation and survival of normal B cells. Although malignant B cells are also subjected on TACI signaling, there is a remarkable intradisease and interindividual variability of TACI expression in B-cell malignancies. The aim of our study was to explore the possible role of TACI signaling in the biology of chronic lymphocytic leukemia (CLL), including its phenotypic and clinical characteristics and prognosis. Ninety-four patients and 19 healthy controls were studied. CLL patients exhibited variable TACI expression, with the majority of cases displaying low to undetectable TACI, along with low to undetectable BAFF and increased APRIL serum levels compared to healthy controls. CLL cells with high TACI expression displayed a better survival capacity in vitro, when cultured with BAFF and/or APRIL. Moreover, TACI expression was positively correlated with the presence of monoclonal gammopathy and inversely with CD11c expression. Therefore, our study provides further evidence for the contribution of BAFF/APRIL signaling to CLL biology, suggesting also that TACI detection might be useful in the selection of patients for novel targeting therapeutic approaches.